Fexagratinib - Abbisko Therapeutics
Alternative Names: ABSK-091; AZD-4547Latest Information Update: 28 Feb 2024
At a glance
- Originator AstraZeneca
- Developer Abbisko Therapeutics; AstraZeneca; Dust Diseases Authority; Institute of Respiratory Health; National Cancer Institute (USA); University of Glasgow; University of Leeds; University of Wisconsin-Madison
- Class Antineoplastics; Benzamides; Phenyl ethers; Piperazines; Pyrazoles; Small molecules
- Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Lymphoma; Multiple myeloma; Solid tumours; Urogenital cancer
- Preclinical Skin cancer
- No development reported Liver cancer
- Discontinued Bladder cancer; Breast cancer; Glioblastoma; Head and neck cancer; Lung cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Liver-cancer in China (PO)
- 23 Jan 2024 Preclinical trials in Solid tumours (Monotherapy) in China (PO) (Abbisko Therapeutics pipeline, January 2024)
- 26 Oct 2022 Pharmacodynamics data from a preclinical studies in Cancer presented at the 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR-2022)